CRSP CRISPR Therapeutics AG Common Shares
CRISPR Therapeutics AG Common Shares (CRSP) trend channel, buy level and 3-month target on Trade The Path. Sector: Healthcare. Listed on NASDAQ. Levels below are fitted to this ticker's own swing highs and lows (Theil–Sen, log-price), then projected 3 months. If this ticker has no settled sample yet, treat the numbers as a geometric read, not a track record. Information only, not financial advice.
In the buy zone, falling this year inside a rising 2.003440873890157-year channel
Price is sitting on the lower trend line — the level that has repeatedly held.
The next few months are read from the last 12 months, not the last 2 years: that channel fits this stock's recent turns at least as well (56% against 48%) and it is the one price is respecting now. The last 2 years stay as context: rising, +10% a year. A stock can be falling inside a channel that still rises over years; that is what this is, and only one of the two can be the near-term expectation. The target of US$56.08 is below the nearest ceiling (US$62.72), so it does not depend on a breakout. What would overturn this: a close below US$55.09 — the floor of the channel being read — after which the trend, not the entry, is what was wrong.
- 2 years read from
- US$54.15 – US$62.72 Rising channel, +10% a year
- Position in that channel
- 8% 0% at the floor, 100% at the ceiling
Price history, with the path projected 3 months forward
- Daily close
- Upper trend line (2 years)
- Lower trend line (2 years)
- The same lines over the last 12 months
- Dashed after today: projected 3 months
- Our buy
- Our target
Suggested path
Buy at or below
US$50.98
level as at 9 Oct 2026
Our target
US$56.08
by 19 Oct 2026
Projected move
10.0%
gross, before costs
Price sits between our buy level and our target.
The lines are drawn where this stock has actually turned: 7 touches on the ceiling, 4 on the floor, each fitted to the slope that catches the most of them. Buying one average daily range below its 50-day mean, on heavier volume than usual and while it is still above its 200-day mean, has come up 791 times; measured against the 6% floor — the least a call has to be worth to be worth making, not what it aims at — 73% cleared it, typically in 34 days, with price going about 5% against the entry along the way (63% in the worst case we have on record). Trades that have not reached the target within 3 months are counted as misses, whatever they are worth at the time. The prices above are this stock’s own — its average, its volatility — but the setup is the same one we apply everywhere: derived on eight unrelated tickers, then confirmed on 87 others it was never fitted to. We deliberately do not tune it to each stock: doing so scores worse on history the tuning never saw — 58% against 71% — because it fits the past rather than the future. On this stock the setup has come up 2 times so far, reaching target 50% of the time — too few to mean much on its own. The sell price is the exit with the highest expected return per day held among the levels this path actually supports — the historical size that path supports, not a farther peak the line never reaches. The fitted path's nearer top is 24% above the entry; 10% is the size that paid the most per day of money tied up here, measured over 146 stretches of this stock’s own record, reached 75% of the time, typically in 10 days. A recovery back to an old high is only published when its expected $/day, dated by when the path itself would get there, truly beats this nearer top. Holding through a dip past this exit would lower that rate. It is a prediction, so it can be revised: if the run tops out before it gets there, the target is cut to what is actually on the table and you are told the same day. An ordinary pullback is not treated as topping out — those go on to make a new high about 8 times in 10, so they are ridden through. What triggers the revision is price closing below its 50-day trend and staying there, after which the odds of recovery fall to roughly 3 in 10.
- Upper line touches
- 7
- Lower line touches
- 4
- Fit confidence
- 48%
- Fitted
- 24 Sept 2026
Company information
Fundamentals are not available for this instrument from the current data provider.
Trend lines are fitted statistically to past swing highs and lows and projected forward on the assumption the same rhythm continues. It often does not. This is information, not advice.